Safety and tolerability of extended-release niacin with laropiprant.


INTRODUCTION Niacin is one of the oldest drugs used in the treatment of dyslipidemia. Previously its use has been limited because of excessive flushing. Now an agent laropiprant (LRP) has been developed, which blocks the flushing pathway. Therefore, it is time to collate available information to assess the safety and tolerability of combining niacin with… (More)
DOI: 10.1517/14740338.2011.638281


2 Figures and Tables